Arbaclofen ER is under clinical development by Osmotica Pharmaceutical and currently in Phase I for Opium (Opioid) Addiction. According to GlobalData, Phase I drugs for Opium (Opioid) Addiction have a 74% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Arbaclofen ER’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Arbaclofen ER overview

Arbaclofen (OS-440) is under development for the treatment of muscle spasticity associated with multiple sclerosis, opioid use disorder and alcohol use disorder. The drug candidate is administered orally as a tablet. It acts bt targeting GABA-B receptor. The drug candidate is developed based on Osmodex technology. It was also under development for the treatment of trigeminal neuralgia and muscle spasm (other spasticity disorders). The drug candidate is an extended release formulation.

Text-to-speech function is limited to 100 characters Options : History : Help : FeedbackClose

Osmotica Pharmaceutical overview

Osmotica Pharmaceutical (Osmotica) is a pharmaceutical company that specializes in drug delivery technologies and neurology based therapies. The company provides product portfolio such as nifedipine, oxybutynin, venlafaxine and desvenlafaxine, among others. It offers capabilities such as formulation research and development, analytical development, bioanalytical development, clinical development and laser drilling technologies, among others. Osmotica primarily provides development of therapies for the treatment of central nervous system (CNS) disorders. The company provides portfolio of products which are in various stages of development focused on the treatment of movement disorders. It also has operations in Argentina and Hungary. Osmotica is headquartered in Marietta, Georgia, the US.

For a complete picture of Arbaclofen ER’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.